S10 E14: Optimizing Access Through OOLD
Published Date:
This episodes features podcast host, Ginger Blackmon, and special guests Jonas Congelli, RPh and Ken Komorny, PharmD, BCPS.
Oncology practices are often doing the prior authorizations, financial assistance, patient education, monitoring, and follow-up care surrounding oral anticancer therapies — while the prescription itself may still be routed somewhere outside the oncology team.
In this episode of the PQI Podcast, Jonas Congelli, RPh, and Ken Komorny, PharmD, BCPS, have an honest conversation about what that disconnect looks like in real-world oncology practice and why Oncology Optimized Limited Distribution (OOLD) has become such an important conversation across cancer care.
Ken shares emerging data from Moffitt Cancer Center showing fewer hospitalizations and improved adherence among patients supported through medically integrated pharmacy services. Jonas discusses the growing momentum behind OOLD, including why 9 of the last 10 oral oncology product launches utilized OOLD models and what still needs to change to better support oncology practices and patients.
The episode also explores:
- What practices lose when visibility into patient therapy management disappears
- Why medically integrated pharmacy care continues showing stronger outcomes
- Operational frustrations oncology teams continue navigating every day
- Where advocacy and policy conversations around oncology access may be headed next